Search results for "kidney"

showing 10 items of 1514 documents

Technetium-99m mercaptoacetyltriglycine clearance: reference values for infants and children.

1995

Six hundred and thirty-nine clearance studies performed in children aged 7 days to 19 years utilizing technetium-99m mercaptoacetyltriglycine (MAG 3) were retrospectively analysed. Standardized conditions for the investigation included: parenteral hydration (60 ml/hxm2 body surface) in addition to normal oral fluid intake, weight-related dose of99mTc-MAG 3 (1 MBq/kg body weight, minimum 15 MBq) and calculation of clearance according to Bubeck et al. Of the 513 children, 169 included in this analysis could be classified as “normal” with regard to their renal function. Normal kidney function was judged by the following criteria: normal GFR for age, normal tubular function (absence of proteinu…

Technetium-99m-MercaptoacetyltriglycineAdultmedicine.medical_specialtyAdolescentUrologychemistry.chemical_elementRenal functionTechnetiumKidneyTechnetium Tc 99m MertiatideReference ValuesmedicineHumansRadiology Nuclear Medicine and imagingChildRetrospective StudiesProteinuriabusiness.industryRefluxInfant NewbornInfantGeneral MedicineSurgerychemistryEl NiñoReference valuesChild PreschoolUltrasonographymedicine.symptombusinessGlomerular Filtration RateEuropean journal of nuclear medicine
researchProduct

Prenatal sonographic chest and lung measurements for predicting severe pulmonary hypoplasia.

1999

Pulmonary hypoplasia was diagnosed sonographically in 32 fetuses from 20 to 33 weeks of gestation. In addition to standard biometry, transverse thoracic diameter (TTD), sagittal thoracic diameter (TSD), thoracic circumference (TC) and lung diameter (LD) were measured in all cases and compared with known nomograms. The fetuses were divided into five groups according to the main sonographic findings: group 1—skeletal dysplasia; group 2—renal agenesis; group 3—diaphragmatic hernia; group 4—hydrothorax; and group 5—others. Severe pulmonary hypoplasia (PH) was diagnosed prenatally in all cases on the basis of LD measurements. In 17 (53.1 per cent) out of 32 cases TTD was below the 5th percentile…

ThoraxLung Diseasesmedicine.medical_specialtyHydrothoraxGestational AgeKidneyUltrasonography PrenatalPulmonary hypoplasiaPregnancyMedicineHumansDiaphragmatic herniaProspective StudiesRenal agenesisLungGenetics (clinical)Hernia DiaphragmaticBone Diseases DevelopmentalLungbusiness.industryRespiratory diseaseObstetrics and GynecologyThoraxmedicine.diseaseHypoplasiaSurgeryFetal Diseasesmedicine.anatomical_structureAgenesisFemaleRadiologybusinessPrenatal diagnosis
researchProduct

The effect of ions at the surface of calcium oxalate monohydrate crystals on cell-crystal interactions

2003

Magnesium is an abundant ion in biologic systems, including renal tubular fluid; however, the precise role of magnesium during the interaction of calcium oxalate crystals with cells has not been previously defined. In addition, the respective roles of calcium and hydrogen ions during the cell-crystal bonding interaction remain poorly defined. Here we report an atomic level three-dimensional study of a single crystal of calcium oxalate monohydrate (COM; whewellite) which was bathed in a solution of magnesium hexahydrate for 1 year. Magnesium was not incorporated into the structure of whewellite to any significant degree. Instead, COM accepted magnesium primarily as an adsorbate in a binding …

Time FactorsCell SurvivalUrologyInorganic chemistryCalcium oxalatechemistry.chemical_elementCrystal structureCalciumengineering.materialKidneyCell Linechemistry.chemical_compoundDogsImaging Three-DimensionalCell AdhesionmedicineAnimalsMagnesiumHypercalciuriaCarbon RadioisotopesIonsCalcium OxalateChemistryMagnesiumWhewelliteEpithelial CellsAdhesionHydrogen-Ion Concentrationmedicine.diseaseMicroscopy FluorescenceMicroscopy Electron ScanningengineeringCalciumCrystallizationSingle crystalUrological Research
researchProduct

Inhibition of giant cell formation by compound 48/80 after infection with herpesvirus hominis

1974

Choline kinase has been found to be a soluble enzyme with a molecular weight of 105,000 in the cytoplasm of primary rabbit kidney cells. It has been purified 150-fold. It was investigated whether the inhibiting effect of Cpd 48/80 on virus-induced giant cell formation is due to interference with this enzyme. Cpd 48/80-dimer was shown to inhibit the choline kinase activityin vitro without a concomitant inhibition of giant cell formation. Likewise, another competitive inhibitor of choline kinase, purinyl-6-histamine, does not prevent giant cell formation. This finding suggests that there is no correlation between choline kinase activity and giant cell formation.

Time FactorsCholine kinaseeducationGalactosamineOleic AcidsBiologyKidneyTritiumCholinechemistry.chemical_compoundCytopathogenic Effect ViralBiosynthesisVirologyAnimalsSimplexvirusp-Methoxy-N-methylphenethylamineCarbon RadioisotopesCells Culturedchemistry.chemical_classificationGlucosamineBinding SitesPhosphotransferasesGeneral MedicineCompound 48/80LipidsVirologyMolecular biologyIn vitroEnzymechemistryEthanolaminesCytoplasmGiant cellDepression ChemicalPhosphatidylcholinesTritiumChromatography Thin LayerRabbitsArchiv f�r die gesamte Virusforschung
researchProduct

The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial

2019

Abstract Background The Artificial Kidney Initiation in Kidney Injury (AKIKI) trial showed that a delayed renal replacement therapy (RRT) strategy for severe acute kidney injury (AKI) in critically ill patients was safe and associated with major reduction in RRT initiation compared with an early strategy. The five criteria which mandated RRT initiation in the delayed arm were: severe hyperkalemia, severe acidosis, acute pulmonary edema due to fluid overload resulting in severe hypoxemia, serum urea concentration > 40 mmol/l and oliguria/anuria > 72 h. However, duration of anuria/oliguria and level of blood urea are still criteria open to debate. The objective of the study is to compar…

Time FactorsHyperkalemiamedicine.medical_treatment[SDV]Life Sciences [q-bio]Medicine (miscellaneous)030204 cardiovascular system & hematologyKidneyurologic and male genital diseases[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrologylaw.inventionTime-to-Treatment03 medical and health sciencesStudy Protocol0302 clinical medicineRandomized controlled triallawOliguriamedicineHumansMulticenter Studies as TopicPharmacology (medical)030212 general & internal medicineRenal replacement therapyProspective StudiesTreatment outcomeRandomized Controlled Trials as TopicMechanical ventilationlcsh:R5-920business.industryRenal replacement therapyAcute kidney injuryRecovery of FunctionInterim analysismedicine.diseasefemale genital diseases and pregnancy complications3. Good healthAcute kidney injuryCritical careAnesthesiaAnuria[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancemedicine.symptombusinesslcsh:Medicine (General)Kidneys Artificial
researchProduct

Use of a Genetically Engineered Strain To Evaluate the Pathogenic Potential of Yeast Cell and Filamentous Forms duringCandida albicansSystemic Infect…

2007

ABSTRACTThe pathogenesis ofCandida albicanssystemic infection is complex and results from the balance between its intrinsic virulence attributes and the host immune responses. Morphogenetic transitions between yeast cell and filamentous forms are considered one of the main virulence attributes inC. albicans. We have examined the pathogenesis of a genetically engineeredC. albicansstrain in which morphogenetic conversions can be externally manipulated in immunodeficient mice; these included B-cell deficient, nude (T cell deficient), SCID (lacking both functional T and B cells), and DBA/2N (C5 deficient with impaired neutrophil activity) mice. We also tested mice severely immunosuppressed by c…

Time FactorsT cellImmunologyCellMice NudeVirulenceMice SCIDKidneyMicrobiologyMicrobiologyFungal ProteinsMiceImmune systemCandida albicansmedicineAnimalsCandida albicansMice Inbred BALB CFungal proteinbiologyCandidiasisbiology.organism_classificationVirologyYeastCorpus albicansMice Inbred C57BLInfectious Diseasesmedicine.anatomical_structureDoxorubicinMice Inbred DBAFemaleParasitologyFungal and Parasitic InfectionsGenetic EngineeringInfection and Immunity
researchProduct

Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. T…

2017

Background Type 2 diabetes mellitus (T2DM) is one of the most common causes of chronic kidney disease and kidney failure. It has been estimated that the annual decline of estimated glomerular filtration rate (eGFR) among patients with T2DM is approximately 2.0-2.5 mL min−1 y−1. Cyclooxygenase-dependent eicosanoids, such as 11-dehydro-thromboxane (Tx)B2, are increased in T2DM patients and are potentially involved in the regulation of renal blood flow. Animal models showed that cyclooxygenase inhibitors, such as aspirin, are associated with improvements in renal plasma flow and eGFR values. Hypothesis The primary end point of the LEDA trial is to evaluate the 1-year decline of eGFR in T2DM pa…

Time Factorskidney disease030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawClinical endpointMedicineRenal Insufficiency030212 general & internal medicineChronicKidneyAspirinkidney disease progressionclinical trialtrialPrognosisType 2 diabetes mellituAspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus Type 2; Disease Progression; Dose-Response Relationship Drug; Double-Blind Method; Follow-Up Studies; Glomerular Filtration Rate; Humans; Prognosis; Renal Insufficiency Chronic; Time Factors; Cardiology and Cardiovascular Medicinemedicine.anatomical_structureAspirin; Cyclooxygenase Inhibitors; Diabetes Mellitus; Type 2; Disease Progression; Dose-Response Relationship; Drug; Double-Blind Method; Follow-Up Studies; Glomerular Filtration Rate; Humans; Prognosis; Renal Insufficiency; Chronic; Time Factors; Cardiology and Cardiovascular MedicineDisease Progressiontype 2 diabetesDrugSettore SECS-S/01 - StatisticaCardiology and Cardiovascular MedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyUrologyRenal functionDose-Response Relationship03 medical and health sciencesDouble-Blind MethodDiabetes MellitusHumansCyclooxygenase InhibitorsRenal Insufficiency Chronickidney disease kidney disease progression type 2 diabetes aspirin trialDose-Response Relationship DrugAspirinbusiness.industryrenal functionmedicine.diseaseSurgeryClinical trialDiabetes Mellitus Type 2Renal blood flowbusinessFollow-Up StudiesKidney disease
researchProduct

Early kinetics of Torque Teno virus DNA load and BK polyomavirus viremia after kidney transplantation

2019

Torque teno virusPolyomavirus InfectionsTransplantationTorque teno virusbusiness.industryViremiaViral Loadmedicine.diseasemedicine.disease_causeKidney TransplantationVirologyBK virusTorque teno virus DNAKineticsTumor Virus InfectionsInfectious DiseasesBK VirusDNA ViralHumansMedicineKidney DiseasesViremiabusinessKidney transplantationTransplant Infectious Disease
researchProduct

Transcription of human neuronal nitric oxide synthase mRNAs derived from different first exons is partly controlled by exon 1-specific promoter seque…

2006

AbstractThe human neuronal nitric oxide synthase (NOS1) gene is subject to extensive splicing. A total of 12 NOS1 mRNA species have been identified. They differ in their 5′ ends and are derived from 12 different first exons (termed exons 1a to 1l). Various cell lines whose NOS1 first exon expression patterns were representative of human brain, skin, and skeletal muscle were identified. These included A673 neuroepithelioma cells, SK-N-MC neuroblastoma cells, HaCaT keratinocyte-like cells, and C2C12 myocyte-like cells. In these cell lines, correlations were found between the exon 1 variants preferentially expressed and the promoter activities of their cognate 5′ flanking sequences. These data…

Transcription Genetic5' Flanking Region5' flanking regionReporter gene assaysSkeletal muscleNitric Oxide Synthase Type IBiologyKidneyHippocampusCell LineRT real-time PCRExonExon trappingGenes ReporterTestisGeneticsHumansRNA MessengerCloning MolecularLuciferasesPromoter Regions GeneticGeneSkinBinding SitesSplice site mutationReverse Transcriptase Polymerase Chain ReactionAlternative splicingGenetic VariationHeartExonsMolecular biologyAlternative SplicingRNA splicingCortexTandem exon duplicationProtein BindingTranscription FactorsGenomics
researchProduct

A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity

2019

Here, we present a potent RNA vaccine approach based on a novel bipartite vector system using trans-amplifying RNA (taRNA). The vector cassette encoding the vaccine antigen originates from an alphaviral self-amplifying RNA (saRNA), from which the replicase was deleted to form a transreplicon. Replicase activity is provided in trans by a second molecule, either by a standard saRNA or an optimized non-replicating mRNA (nrRNA). The latter delivered 10- to 100-fold higher transreplicon expression than the former. Moreover, expression driven by the nrRNA-encoded replicase in the taRNA system was as efficient as in a conventional monopartite saRNA system. We show that the superiority of nrRNA- ov…

Translational efficiencyGenetic VectorsRNA-dependent RNA polymeraseHemagglutinin (influenza)Hemagglutinin Glycoproteins Influenza VirusBiologyAntibodies ViralMadin Darby Canine Kidney CellsMice03 medical and health sciencesDogsImmunogenicity VaccineInfluenza A Virus H1N1 Subtype0302 clinical medicineOrthomyxoviridae InfectionsCricetinaeInfluenza HumanDrug DiscoveryGeneticsAnimalsHumansViral Replicase Complex ProteinsRepliconMolecular BiologyGene030304 developmental biologyPharmacologyMice Inbred BALB C0303 health sciencesMessenger RNAVaccinationRNATranslation (biology)Antibodies NeutralizingSemliki forest virusVirologyHEK293 CellsInfluenza Vaccines030220 oncology & carcinogenesisbiology.proteinRNA ViralMolecular MedicineFemaleOriginal ArticleMolecular Therapy
researchProduct